Institut National De La Sante Et De La Recherche Medicale

Other

Centre National De La Recherche Scientifique

Institut Pasteur

Glaxosmithkline Biologicals Sa

Ludwig Institute for Cancer Research Limited

Sorbonne Université

Inserm

Sandra Morel

Thierry R Boon-Falleur

Benoit Van Den Eynde

Claude Leclerc

Daniel Ladant

Cecile Bauche

Cécile Bauche

Gilles Dadaglio

Benoît Van Den Eynde

Benoit Laurent Salomon

G&eacute;rard De Giiovanni

Charlotte Véronique Pouchy

Nathalie Raoul Liliane Vanerheyde

Annie Ooms

Beno&icirc;t Van Den Eynde

The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.

Use of adjuvants for the prevention and/or treatment of autoimmune diseases

An immunogenic composition comprising a recombinant protein comprising aCyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

[object Object]

The invention relates to peptides which bind to HLA-B35 molecules, leading to recognition and lysis of the resulting complexes by cytolytic T cells. Also a part of the invention are nucleic acid molecules which encode these peptides, and uses of each of these. The molecules are derived, in some cases, from tyrosinase, and portions of the tyrosinase molecule and portions of nucleic acid molecules which encode tyrosinase are also a part of the invention.

Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof

Growing community of inventors

Brussels, Belgium

Sandra Morel